These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44 related articles for article (PubMed ID: 29305554)
21. Possible mechanisms for intravenous immunoglobulin-associated hemolysis: clues obtained from review of clinical case reports. Padmore R Transfusion; 2015 Jul; 55 Suppl 2():S59-64. PubMed ID: 26174898 [TBL] [Abstract][Full Text] [Related]
22. Specifications for anti-A and anti-B in intravenous immunoglobulin: history and rationale. Thorpe SJ Transfusion; 2015 Jul; 55 Suppl 2():S80-5. PubMed ID: 26174902 [TBL] [Abstract][Full Text] [Related]
23. Hemolysis from ABO Incompatibility. Simmons DP; Savage WJ Hematol Oncol Clin North Am; 2015 Jun; 29(3):429-43. PubMed ID: 26043383 [TBL] [Abstract][Full Text] [Related]
24. Safeguarding immune globulin recipients against hemolysis: what do we know and where do we go? Scott DE; Epstein JS Transfusion; 2015 Jul; 55 Suppl 2():S122-6. PubMed ID: 26174890 [No Abstract] [Full Text] [Related]
25. Anti-A and anti-B: what are they and where do they come from? Branch DR Transfusion; 2015 Jul; 55 Suppl 2():S74-9. PubMed ID: 26174901 [TBL] [Abstract][Full Text] [Related]
26. [Efficacy and safety of intravenous immunoglobulins in the management of neonatal hyperbilirubinemia due to ABO incompatibility: a meta-analysis]. Cortey A; Elzaabi M; Waegemans T; Roch B; Aujard Y Arch Pediatr; 2014 Sep; 21(9):976-83. PubMed ID: 25125032 [TBL] [Abstract][Full Text] [Related]
31. Incidence and risk factors for intravenous immunoglobulin-related hemolysis: A systematic review of clinical trial and real-world populations. Cuesta H; El Menyawi I; Hubsch A; Hoefferer L; Mielke O; Gabriel S; Shebl A Transfusion; 2022 Sep; 62(9):1894-1907. PubMed ID: 35916266 [TBL] [Abstract][Full Text] [Related]
32. Oral administration of Chinese herbal medicine during gestation period for preventing hemolytic disease of the newborn due to ABO incompatibility: A systematic review of randomized controlled trials. Cao H; Wu R; Han M; Caldwell PHY; Liu JP PLoS One; 2017; 12(7):e0180746. PubMed ID: 28719639 [TBL] [Abstract][Full Text] [Related]
33. Therapeutic strategies in management of the highly HLA-sensitized and ABO-incompatible transplant recipients. Jordan SC; Peng A; Vo AA Contrib Nephrol; 2009; 162():13-26. PubMed ID: 19001810 [TBL] [Abstract][Full Text] [Related]
34. Current progress in ABO-incompatible liver transplantation. Tanabe M; Kawachi S; Obara H; Shinoda M; Hibi T; Kitagawa Y; Wakabayashi G; Shimazu M; Kitajima M Eur J Clin Invest; 2010 Oct; 40(10):943-9. PubMed ID: 20636381 [TBL] [Abstract][Full Text] [Related]
35. Modulating alloimmune responses with plasmapheresis and IVIG. Warren DS; Simpkins CE; Cooper M; Montgomery RA Curr Drug Targets Cardiovasc Haematol Disord; 2005 Jun; 5(3):215-22. PubMed ID: 15975035 [TBL] [Abstract][Full Text] [Related]
36. ABO and platelet transfusion therapy. Cooling L Immunohematology; 2007; 23(1):20-33. PubMed ID: 17425412 [No Abstract] [Full Text] [Related]
37. Do immune complexes play a role in hemolytic sequelae of intravenous immune globulin? Zimring JC Transfusion; 2015 Jul; 55 Suppl 2():S86-9. PubMed ID: 26174903 [TBL] [Abstract][Full Text] [Related]